Jasper Therapeutics initiates strategic review including potential sale or wind-down

Jasper Therapeutics, Inc.

Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.
Options include sale of assets/licensing, collaboration, merger, business combination, or orderly wind-down.
Company to continue evaluating cost-saving measures to preserve cash during the process.
No defined timeline for the review; no assurance any transaction will be consummated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.